Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome
Phase 3
Completed
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT20240305061171N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Polycystic ovary syndrome according to Rotterdam criteria
Age 18 to 40 years
The number of antral follicles (AFC) above 20
Anti-Müllerian hormone (AMH) more than 3.36 ng/ml
Body mass index (BMI) less than 30 kg/m2
Exclusion Criteria
Suffering from endometriosis
Decreased ovarian reserve
Chromosomal abnormalities
History of sensitivity to drugs that inhibit dopamine or cabergoline
Patients who do not take the desired drugs on a daily basis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cabergoline's and hydroxychloroquine's efficacy in preventing OHSS in PCOS patients?
How do cabergoline and hydroxychloroquine compare to standard-of-care treatments for OHSS prevention in PCOS patients undergoing infertility therapy?
Which biomarkers could predict PCOS patient response to cabergoline or hydroxychloroquine in preventing OHSS?
What are the potential adverse events associated with cabergoline and hydroxychloroquine use in OHSS prevention and how can they be managed?
Are there combination therapies involving cabergoline or hydroxychloroquine that show promise in mitigating OHSS in PCOS patients undergoing assisted reproductive treatments?